Home / Business and Economy / CareDx Surges on Finalized Medicare Coverage
CareDx Surges on Finalized Medicare Coverage
19 Jul
Summary
- Medicare finalized coverage for CareDx's transplant surveillance tests.
- The decision clarifies testing frequency limits for Medicare patients.
- This reduces reimbursement uncertainty for CareDx's core products.
Medicare has finalized a Local Coverage Determination (LCD) for molecular testing aimed at monitoring solid organ transplant rejection. This ruling affirms coverage for CareDx's AlloSure Kidney, AlloMap, and AlloSure Heart, and AlloSure Lung surveillance tests. Defined testing limits are now established for the initial three years following a transplant.
This finalized LCD removes a significant reimbursement overhang for CareDx, clarifying how frequently clinicians can utilize these diagnostics within Medicare-covered pathways. The decision, effective August 30, 2026, means investors will closely watch the Q2 2026 earnings call on July 30 for management's insights on testing utilization against the new limits.
CareDx's investment narrative now centers on sustained clinical adoption and stable reimbursement, with the LCD providing policy clarity. While some analysts remain cautious about potential bundling and pricing pressures, the finalized Medicare framework offers a more defined outlook for CareDx's transplant surveillance portfolio.
